Personalized medicine and orphan drugs – a public health perspective

Cikk címe: Personalized medicine and orphan drugs – a public health perspective

Szerzők: MD Phd Bochenek Tomasz

Intézmények: Department of Drug Management

Évfolyam: XII. évfolyam

Lapszám: 2013. /

Oldal: 50-53

Terjedelem: 4

Rovat:

Alrovat:

Absztrakt:

The drugs from area of the personalized medicine and the orphan drugs offer both hope and challenge to the contemporary health care systems. The health technology assessment can help in making decisions on financing the personalized medicine interventions. The status of rarity of diseases and the orphan status of drugs used in their treatment can have very complex implications, resulting in the extremely high expenditures. In the era of economic slowdown the open discussion is needed on finding reasonable and new solutions for the market introduction and the subsequent financing of the orphan drugs.

Abstract:

The drugs from area of the personalized medicine and the orphan drugs offer both hope and challenge to the contemporary health care systems. The health technology assessment can help in making decisions on financing the personalized medicine interventions. The status of rarity of diseases and the orphan status of drugs used in their treatment can have very complex implications, resulting in the extremely high expenditures. In the era of economic slowdown the open discussion is needed on finding reasonable and new solutions for the market introduction and the subsequent financing of the orphan drugs.

Szerző Intézmény
MD Phd Bochenek Tomasz Department of Drug Management

[1] Lee M-S, Flammer AJ, Lerman LO, Lerman A: Personalized Medicine in Cardiovascular Diseases, Korean Circ J. 2012;42:583-591.
[2] Clark A E: Sequence Thyself: Personalized Medicine and Therapies for the Future. 2012 Yale Healthcare Conference, Yale Journal of Biology and Medicine 85 (2012): 421-424.
[3] Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A-P, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J: for Personalized Medicine Development and Reimbursement Working Group: Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group, Value in Health, 15. 2012: 1162–1171.
[4] Flowers CR, Veenstra D: The Role of Cost- Effectiveness Analysis in the Era of Pharmaco genomics, Pharmacoeconomics, 2004, 22 (8): 481-493.
[5] Simoens S, Cassiman D, Dooms M, Picavet E: Orphan drugs for rare diseases. Isnʼt it time to revisit their special market access status? Drugs, 2012. 72 (11): 1437-1443.
[6] Winquist E, Bell CM, Clarke JTR, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D: An Evaluation Framework for Funding Drugs for Rare Diseases, Value in Health, 2012. 15: 982-986.
[7] Herper M: The worldʼs most expensive drugs. Forbes. 2/22/2010 http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html (accessed 17.06.2013)
[8] Wellman-Labadie O, Zhou Y: The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010. May 95 (2-3): 216-28.